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用透析法成功制备出了粒径在 200~500 nm 的纳米粒子。（3）经叶酸修饰，并载
有多西紫杉醇的 PA 纳米粒子载药量为 1.9%、包封率为 20.6%。（4）经甲氨蝶呤
修饰，并载有多西紫杉醇的 PA 纳米粒子，多西紫杉醇的载药量为 2.3%，包封率



















Presently, malignant tumor is a serious threat to human health. Chemotherapy is 
usually impotent in effectible treatment according to its unfavorable specificity 
towards tumors and great side effects which leading to great pain to the patients.As a 
result,the most important challenge for researchers is to improve thespecificity and 
safety of anti-cancer drugs, reduce side effects, to amelioratethe quality of 
patients’life.FA receptor, a specific and high affinity receptor for FA, has been found 
to be widely distributed on the cancer cell and generally overexpressed on the 
membrane surface of cancer cell, while it is highly restricted in the normal cell in a 
proof-of-principle experiment. As such, one pivotal strategy to develop the effective 
nanoparicle-based drug delivery system is the functionalization of a targeting ligand 
such as FA on the surface of nanoparticles via FA receptor mediated endocytosis. 
MTX is an analogue of FA because of chemical structure of MTX analogous to that of 
FA, regardless the key features that MTX has an amino group whereas FA has a 
hydroxyl group at the 4-position of pteridine ring. Despite the lower affinity of FA 
receptorfor MTX compared to FA, MTX can specifically bind to FA receptor. And, 
MTX is a widely effective anticancer drug in clinic application by virtue of its 
inhibition of enzymatic activity of dihydrofolate reductase （DHFR）  protein 
localized in the cytosol in cellular FA metabolism. For this reason, MTX exhibits not 
only an apoptosis-inducing effect but also a potentially targeting effect. So, one would 
wonder whether it is possible to take advantage of its novel dual-acting role to 
develop the targeted nanoparicle-based drug delivery system.  
The present work includes: （1）Synthesize pullulan acetate（PA） with acetic 
anhydride. （2） Folate and MTX were coupled to pullulan acetate （PA）.The product 
was characterized by 1H NMR spectroscopy. The degree of folate and MTX 
substitution （DS） calculated by ultraviolet spectrometry is 0.243 and 0.261 per sugar 
residues of PA. （3）Folate（or MTX） conjugated pullulan acetate nanoparticles and 















were performed to study the behavior of the drug system 
The main findings are as follows:（1） Successful synthesis of folic conjugated 
acetate pullulan and methotrexate conjugated acetate pullulan; （2）The folate acid 
modified DTX-loading nanoparticles （DTX-FPA-NPs）, MTX modified nanoparticles 
（MPA-NPs）and MTX modified DTX-loading nanoparticles （DTX-MPA-NPs）
were preparedDTX-FPA-NPs’sdrug-loading and entrapment efficiencyrespectively 
were 1.9% and 20.6%.MPA-NPs’ MTX-loading efficiency were 31.1%. 
DTX-MPA-NPs’s MTX-loading and DTX-loading efficiencyrespectively were 2.3% 
and 30.4%. （ 3 ）  It’s shownby Cytotoxicity test,DTX-MPA-NPs is higher 
cytotoxicthan DTX-FPA-NPs and MPA-NPs. 
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1.2.1   纳米给药系统的定义 



































表 1.1 不同粒径的药物载体体内靶向的部位[5] 




<50 nm 穿过肝脏或通过淋巴传输到脾和骨髓，也可到达肿瘤组织最终进入肝脏 
0.1 μm~0.2 μm 被网状内皮系统吸收，最后富集于肝、脾中 
1 μm 白细胞吞噬 
2 μm~12 μm 毛细血管摄取，不仅可到达肺，也可进入肝、脾 
7 μm~12 μm 在肺中富集 






































































































图 1.1 甲壳素和壳聚糖的化学结构 




明胶可以分为酸法明胶（A 型）和碱法明胶（B 型）。A 型明胶的等电点为 7~9，
B 型明胶等电点为 4.7~5。两者的成囊性或成球性无明显差别，都可被生物降解，
几乎无抗原性，可根据药物对酸碱性的要求选用 A 型或 B 型明胶。明胶为淡黄
色至黄色的，半透明的，微带光泽的颗粒或薄片状固体；无臭，潮湿后易为细菌
分解；在水中久浸会吸水膨胀并软化形成凝胶，重量可增加 5~10 倍；在热水、
醋酸或甘油与水的热混合液中溶解后，水溶液的粘度在 0.2~0.75 cPa 之间，在乙
醇、氯仿或乙醚等溶剂中不溶。明胶作为一种胶体，其最重要特性是在 35~40℃
的水中能形成凝胶或胶体，在较高温度下，可以形成溶液。在 40℃以上明胶可
缓慢解聚并降低成胶力，在 65℃以上解聚加快，80℃加热 1 h，其成胶力降低 50%，
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